Company Description
GenEmbryomics is a genomics-based company with a mission dedicated to empowering families to have healthy children by providing in-vitro fertilization patients and providers unparalleled insights into an embryo's genetic disease.
Our flagship test Panacea-GenomeScreen™ offers preimplantation genetic testing (“PGT”) via whole genome sequencing (“WGS”) of individuals, couples and IVF embryos.
Through our test, which we intend to launch commercially in the third quarter of the fiscal year ended June 30, 2025, IVF clinics can gain an actionable genome report screen for over 3,200 severe and fatal genetic diseases, enabling deeper understanding and greater confidence by clinicians and patients undertaking fertility treatments.
The test will utilize our proprietary genome analysis algorithms, and are embedded within the platform to prioritize and generate reports.
Prospective parents will be able to access the information provided through PGT-WGS reports provided through our proprietary artificial intelligence platform to choose the healthiest start for future generations.
| Country | Australia |
| Founded | 2019 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Nicholas M. Murphy |
Contact Details
Address: Level 14, Australia Square, 264-278 George Street Sydney, NSW 2000 Australia | |
| Phone | +61411282401 |
| Website | genembryomics.com |
Stock Details
| Ticker Symbol | XGEN |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $4.75 |
| CIK Code | 0002038033 |
Key Executives
| Name | Position |
|---|---|
| Nicholas M. Murphy | Chief Executive Officer and Managing Director |
| Kathryn Andrews | Chief Financial Officer |
| Paul K. M. Viney | Chairman and Independent Director |
| Nicholas J. Burrows | Independent Director |
| Santiago Munné Blanco | Non-Independent Director |
| Saadia Basharat | Independent Director |
| Teresa R. Burleson | Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 20, 2025 | F-1 | Registration statement for certain foreign private issuers |
| Jan 21, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Dec 20, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 24, 2024 | DRS | [Cover] Draft Registration Statement |